TIKOMED successfully closed fundraising of 8 Million Euros

Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB® program and the IBSOLVMIR® program.

TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program).

“I’m delighted that we have successfully completed our latest fundraising, which demonstrate both the level of interest and trust in our clinical program from investors”, said Anders Kristensson, CEO of TIKOMED.

Tags: